Navamedic 과거 수익 실적

과거 기준 확인 1/6

Navamedic은 연평균 57.2%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 13.1%였습니다. 매출은 연평균 24.8%의 비율로 증가했습니다. Navamedic의 자기자본이익률은 7.4%이고 순이익률은 3.7%입니다.

주요 정보

57.2%

수익 성장률

72.4%

EPS 성장률

Pharmaceuticals 산업 성장	12.4%
매출 성장률	24.8%
자기자본 수익률	7.4%
순이익	3.7%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

수익 및 비용 분석

Navamedic 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OB:NAVA 수익, 비용 및 수입 (NOK Millions )
날짜	수익	수익	G+A 비용
30 Sep 24	526	20	69
30 Jun 24	543	27	67
31 Mar 24	511	-11	68
31 Dec 23	512	3	64
30 Sep 23	503	31	80
30 Jun 23	454	23	101
31 Mar 23	441	43	57
31 Dec 22	382	29	48
30 Sep 22	356	12	59
30 Jun 22	327	8	47
31 Mar 22	283	4	49
31 Dec 21	278	1	44
30 Sep 21	244	-7	50
30 Jun 21	237	-6	38
31 Mar 21	213	-8	46
31 Dec 20	210	-16	33
30 Sep 20	202	-22	58
30 Jun 20	194	-24	33
31 Mar 20	199	-26	34
31 Dec 19	189	-16	33
30 Sep 19	193	-1	32
30 Jun 19	189	0	27
31 Mar 19	187	10	25
31 Dec 18	184	4	26
30 Sep 18	177	-20	30
30 Jun 18	178	-13	28
31 Mar 18	222	-20	30
31 Dec 17	258	-16	30
30 Sep 17	294	3	31
30 Jun 17	315	4	32
31 Mar 17	292	-9	31
31 Dec 16	274	-11	31
30 Sep 16	258	-28	31
30 Jun 16	254	-30	30
31 Mar 16	247	-17	28
31 Dec 15	248	-11	26
30 Sep 15	245	-4	23
30 Jun 15	242	1	21
31 Mar 15	242	1	20
31 Dec 14	223	-1	19
30 Sep 14	204	1	19
30 Jun 14	182	-2	19
31 Mar 14	161	-3	20
31 Dec 13	152	-1	20

양질의 수익: NAVA 에는 NOK11.3M 큰 일회성 손실이 있습니다. NOK11.3M 은 지난 12개월 간의 재무 결과에 30th September, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: NAVA 의 현재 순이익 이익률 (3.7%) 작년보다 낮습니다 (6.1%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NAVA 지난 5년 동안 수익을 창출하여 매년 57.2% 수익을 올렸습니다.

성장 가속화: NAVA 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: NAVA 은 지난 1년 동안 마이너스 수익 성장( -36.5% )을 기록하여 Pharmaceuticals 업계 평균( 8.8% ).

Navamedic 과거 수익 실적

과거 기준 확인 1/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

First quarter 2024 earnings released

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Recent updates

Consensus EPS estimates fall by 21%

Chief Financial Officer recently bought kr476k worth of stock

Navamedic Launches Eroxon in Finland

New minor risk - Profit margin trend

Third quarter 2024 earnings released

Investor sentiment deteriorates as stock falls 17%

Chief Executive Officer exercised options to buy kr2.2m worth of stock.

Consensus EPS estimates fall by 12%

Director recently bought kr1.5m worth of stock

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

Price target decreased by 7.1% to kr45.50

First quarter 2024 earnings released

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?